

Scott C Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5538960/publications.pdf>

Version: 2024-02-01

51
papers

2,114
citations

535685

17
h-index

274796

44
g-index

51
all docs

51
docs citations

51
times ranked

3259
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 74-79.	2.0	6
2	Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 880-889.	0.4	0
3	Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 192.e1-192.e9.	0.8	6
4	Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. <i>BJUI Compass</i> , 2022, 3, 383-391.	0.7	3
5	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology Oncology</i> , 2022, 5, 494-502.	2.6	21
6	Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy. <i>Clinical Oncology</i> , 2021, 33, 181-190.	0.6	9
7	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	0.8	52
8	Unenhanced MRI of the abdomen and pelvis for surveillance of patients with stage 1 testicular cancer post-radical orchiectomy. <i>Abdominal Radiology</i> , 2021, 46, 1157-1162.	1.0	3
9	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab082.	1.4	17
10	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1274-1305.	0.8	67
11	Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1041-1047.	2.0	13
12	Impact of Treating Physician on Radiation Therapy Related Severe Toxicities in Men with Prostate Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e292-e300.	1.1	2
13	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 353-358.	0.3	2
14	Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. <i>Cancers</i> , 2021, 13, 2844.	1.7	10
15	A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. <i>Cancers</i> , 2021, 13, 4257.	1.7	10
16	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	0.9	65
17	Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 593-601.	0.8	45
18	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E588-E593.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1179-1188.	0.4	10
20	Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. , 2020, 47, E86-E106.		10
21	Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?. <i>Current Urology Reports</i> , 2019, 20, 53.	1.0	11
22	A A Canadian consensus forum on the management of patients with advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, E137-E149.	0.3	15
23	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1531-1543.	5.1	362
24	Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. <i>Clinical Oncology</i> , 2019, 31, 630-636.	0.6	19
25	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 50-54.	2.5	2
26	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 420-426.	0.3	9
27	Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S26-S30.	0.2	2
28	External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 2165-2172.	6.3	279
29	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2019, 201, 528-534.	0.2	57
30	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3411-3430.	0.8	118
31	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018, 8, 354-360.	1.1	151
32	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2018, , .	0.2	16
33	Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, 351-360.	0.3	8
34	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. <i>BJU International</i> , 2018, 122, 744-753.	1.3	60
35	Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT). <i>Journal of Radiosurgery and SBRT</i> , 2018, 5, 217-227.	0.2	3
36	Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer. <i>Annals of Internal Medicine</i> , 2017, 167, 341.	2.0	35

#	ARTICLE	IF	CITATIONS
37	Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience. <i>Journal of Radiation Oncology</i> , 2017, 6, 379-385.	0.7	1
38	Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline. <i>Canadian Urological Association Journal</i> , 2016, 10, 332.	0.3	16
39	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Clinical Oncology</i> , 2016, 34, 2182-2190.	0.8	285
40	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. <i>Canadian Urological Association Journal</i> , 2016, 10, 90.	0.3	6
41	Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. <i>Systematic Reviews</i> , 2015, 4, 114.	2.5	16
42	Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. <i>European Radiology</i> , 2015, 25, 1247-1256.	2.3	24
43	Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters. <i>British Journal of Radiology</i> , 2014, 87, 20130813.	1.0	28
44	Radiotherapy after Radical Prostatectomy: Treatment Recommendations Differ between Urologists and Radiation Oncologists. <i>PLoS ONE</i> , 2013, 8, e79773.	1.1	15
45	Postoperative Radiotherapy After Radical Prostatectomy: Adjuvant or Salvage?. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 167-175.	0.2	0
46	Local treatment of metastatic cancer—killing the seed or disturbing the soil?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 504-506.	12.5	38
47	Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 939-951.	1.1	8
48	Mobilization of Circulating Vascular Progenitors in Cancer Patients Receiving External Beam Radiation in Response to Tissue Injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 220-224.	0.4	13
49	Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: Dosimetric evaluation. <i>Radiotherapy and Oncology</i> , 2009, 90, 99-105.	0.3	79
50	Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2008, 88, 1-9.	0.3	79
51	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	4